A month has gone by since the last earnings report for Ametek (AME - Free Report) . Shares have lost about 8.5% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Ametek due for a breakout? Well, first let's take a quick look at the latest earnings report in order to get a better handle on the recent catalysts for AMETEK, Inc. before we dive into how investors and analysts have reacted as of late.
AMETEK Q2 Earnings Surpass Expectations, Revenues Rise Y/YAMETEK, Inc. reported second-quarter 2026 results, wherein both top and bottom lines surpassed the Zacks Consensus Estimate.
AMETEK reported its second-quarter non-GAAP earnings of $2.09 per share, which beat the Zacks Consensus Estimate by 5%. The figure increased 17% year over year.
AMETEK’s top line of $2.04 billion surpassed the Zacks Consensus Estimate by 4.5%. The figure increased 15% year over year.
The company experienced an increase in sales in its largest EIG segment, along with a year-over-year improvement in the EMG segment.
AMETEK’s Q2 2026 DetailsEIG sales (64.6% of total revenues) in the second quarter were $1.32 billion, up 14% from the year-ago quarter’s reported figure. Our model estimate for EIG sales was pegged at $1.26 billion.
In the second quarter, revenues from EMG (35.4% of total revenues) were $723.2 million, up 17% from the year-ago quarter. Our model estimate for EMG sales was pegged at $688.6 million.
For the second quarter, adjusted operating income increased 18% year over year to $544.4 million. The operating margin expanded 60 basis points (bps) from the year-ago quarter.
EIG's second-quarter adjusted operating income was $384.7 million, up 12% year over year.
EMG’s adjusted operating income in the quarter increased 32% to $190.5 million.
AME’s Balance Sheet DetailsAs of June 30, 2026, AME had cash and cash equivalents of $495.4 million compared with the previous quarter’s $481.25 million.
As of June 30, 2026, AME’s long-term debt was $1.056 billion, down marginally from the previous quarter’s $1.062 billion.
AME Raises Guidance for 2026For 2026, AME expects overall sales to increase 10% year over year, up from the prior guidance of overall sales to be up in the high single digits. The company expects its adjusted earnings per share to be in the range of $8.20-$8.30, indicating an increase of 10% to 12% year over year, up from its prior guidance of $7.94-$8.14.
For the third quarter of 2026, the company expects overall sales to be up in the high single digits compared with the same period last year. Adjusted earnings for the third quarter are expected to be in the range of $2.08-$2.10, indicating a year-over-year increase of 10-11%.
How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a upward trend in fresh estimates.
VGM ScoresCurrently, Ametek has a average Growth Score of C, however its Momentum Score is doing a lot better with an A. However, the stock has a score of D on the value side, putting it in the bottom 40% for value investors.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
OutlookEstimates have been trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Ametek has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
, /PRNewswire/ -- AMETEK, Inc. (NYSE: AME) today announced that it has completed its previously announced acquisition of a portfolio of instrumentation businesses from Indicor, LLC, ("Indicor Instrumentation") in an all‑cash transaction valued at $5.0 billion.
Indicor Instrumentation is a group of leading businesses that design and manufacture mission-critical solutions for demanding industrial and scientific applications. Its products serve customers across attractive end markets that align closely with AMETEK's existing portfolio and generate a substantial base of recurring revenue from consumables, services and aftermarket support.
"We are excited to complete this highly strategic acquisition and to welcome the Indicor Instrumentation team to AMETEK," said David A. Zapico, AMETEK Chairman and Chief Executive Officer. "With its mission-critical solutions, deep technical expertise, and strong positions in attractive end markets, Indicor Instrumentation is an excellent fit with AMETEK. We also see meaningful opportunities to create value through integration into our proven operating model."
Indicor Instrumentation is expected to contribute approximately $350 million to AMETEK's 2026 sales and is expected to be modestly accretive to AMETEK's 2026 adjusted earnings. The Indicor Instrumentation businesses join AMETEK's Electronic Instruments Group (EIG) and Electromechanical Group (EMG) based on product offerings and market alignment.
Corporate Profile
AMETEK (NYSE: AME) is a leading global provider of industrial technology solutions serving a diverse set of attractive niche markets with annualized sales of approximately $9.0 billion. The AMETEK Growth Model integrates the Four Growth Strategies - Operational Excellence, Technology Innovation, Global and Market Expansion, and Strategic Acquisitions - with a disciplined focus on cash generation and capital deployment. AMETEK's objective is double-digit percentage growth in earnings per share over the business cycle and a superior return on total capital. Founded in 1930, AMETEK has been listed on the NYSE for over 95 years and is a component of the S&P 500. For more information, visit www.ametek.com.
Contact:
Kevin Coleman
Vice President, Investor Relations and Treasurer
[email protected]
Phone: 610-889-5247
Ametek (AME - Free Report) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.
The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.
Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts, since these are mostly driven by subjective factors that are hard to see and measure in real time. In these situations, the Zacks rating system comes in handy because of the power of a changing earnings picture in determining near-term stock price movements.
Therefore, the Zacks rating upgrade for Ametek basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.
Most Powerful Force Impacting Stock PricesThe change in a company's future earnings potential, as reflected in earnings estimate revisions, has proven to be strongly correlated with the near-term price movement of its stock. That's partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their transaction of large amounts of shares then leads to price movement for the stock.
For Ametek, rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company's underlying business. And investors' appreciation of this improving business trend should push the stock higher.
Harnessing the Power of Earnings Estimate RevisionsEmpirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, so it could be truly rewarding if such revisions are tracked for making an investment decision. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> .
Earnings Estimate Revisions for AmetekThis maker of electronic instruments and electromechanical devices is expected to earn $8.31 per share for the fiscal year ending December 2026, which represents no year-over-year change.
Analysts have been steadily raising their estimates for Ametek. Over the past three months, the Zacks Consensus Estimate for the company has increased 2.4%.
Bottom LineUnlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of "buy" and "sell" ratings for its entire universe of more than 4,000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a "Strong Buy" rating and the next 15% get a "Buy" rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.
You can learn more about the Zacks Rank here >>>
The upgrade of Ametek to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.
3D Printing, or additive manufacturing, is emerging as a transformative force in modern manufacturing, offering companies a faster, more flexible and cost-efficient way to produce complex products. By turning digital designs into physical objects layer by layer, additive manufacturing enables greater customization, minimizes material waste and reduces production time compared with conventional manufacturing methods.
Since its emergence in the 1980s, the technology has evolved beyond its early use in prototyping into a technologically advanced manufacturing process. 3D Printing is gaining traction across a wide range of end markets, including medical prosthetics, aerospace components, architectural models and consumer products. Companies like Xometry (XMTR - Free Report) , Proto Labs (PRLB - Free Report) and Stratasys (SSYS - Free Report) remain key players in this space.
Unlike traditional subtractive manufacturing, additive manufacturing reduces material waste and enables production of complex structures that were once difficult, costly or even considered impossible to produce. It enables localized production, thus shortening supply chains and lowering transportation costs. On-demand manufacturing reduces the need for large inventories, which is especially useful for industries with seasonal demand or urgent replacement-part needs. Companies are thus increasingly adopting 3D printing driven by its cost advantages and sustainability benefits.
Adoption is gaining across healthcare, aerospace, automotive and consumer goods. In aerospace, the technology is used to produce lightweight yet durable aircraft and spacecraft components. The automotive industry relies on 3D printing for prototyping, tooling and customized parts. In healthcare, it enables the production of patient-specific medical devices and prosthetics, and ongoing progress in tissue and organ printing could significantly influence the future of modern medicine.
North America remains the leading market, accounting for more than 35% of global share due to strong research investments, supportive government policies and advanced manufacturing capabilities. Asia-Pacific countries, particularly China and India, are rapidly expanding adoption to strengthen their industrial competitiveness.
We believe 3D Printing presents compelling growth opportunities for investors, supported by an expanding addressable market and a strong innovation pipeline.
Our 3D Printing Screen makes it easy to identify high-potential stocks in this space. Currently, stocks like Proto Labs, Stratasys, AMETEK (AME - Free Report) , ATI Inc. (ATI - Free Report) and Carpenter Technology (CRS - Free Report) look lucrative.
Ready to uncover more transformative thematic investment ideas? Explore 39 cutting-edge investment themes with Zacks Thematic Investing Screens and discover your next big opportunity.
5 Must-Have 3D Printing Stocks for Your PortfolioProto Labs is widely recognized as the world’s fastest digital manufacturing platform for rapid prototypes and on-demand production parts. Since its inception, it has manufactured more than 700 million parts, catering to more than 300,000 customers.
Originally focused on prototypes and simpler components, Protolabs has expanded into complex parts and full-scale production. Strategic acquisitions have also strengthened its capabilities, including FineLine in 2014 to introduce 3D printing, Alphaform in October 2015 to expand 3D printing services in Europe and RAPID in 2017 to add sheet-metal manufacturing. Through the acquisition of 3D Hubs, Inc., which was rebranded to Protolabs Network in 2021, it provides customers access to a global network of premium manufacturing partners.
In February 2026, the company launched ProDesk, an Artificial Intelligence (AI) enabled manufacturing platform to accelerate projects from prototyping to production. It features AI-driven manufacturability analysis across injection molding, CNC machining and 3D printing services for instant feedback on parts before they enter production. The platform also allows users to customize quotes based on materials, finishes, secondary operations and lead-time requirements.
Proto Labs is also positioning itself to capitalize on the expected surge in growth in the global drone market driven by rising aerospace and defense spending and expanding commercial applications. The company has expanded manufacturing capabilities and offers quick-turn CNC machining for end-use metal and plastic parts with tighter tolerances, greater precision and broader functional and cosmetic finishes, along with advanced 3D printing technologies that enable drone manufacturers greater design freedom to produce lightweight components that meet strict performance requirements. PRLB currently carries a Zacks Rank #2 (Buy).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Stratasys has been leading the global shift to additive manufacturing with innovative 3D printing solutions for various industries including aerospace, automotive, consumer products, and healthcare.
Stratasys is expanding its portfolio through strategic partnerships and acquisitions. Earlier this year, it collaborated with industrial metal 3D printing company Tritone Technologies. Tritone’s MoldJet technology, a breakthrough metal and ceramic additive manufacturing process, complements Stratasys’ polymer jetting expertise and advances its position as a comprehensive, end-to-end provider of a broad range of AM solutions
SSYS has inked a deal to acquire MarkForged, Inc., a leading provider of end-to-end Fused Filament Fabrication (FFF) solutions. The transaction is expected to close later this year. By leveraging Continuous Carbon Fiber technology, MarkForged enables industries such as aerospace, defense, automotive, and food and beverage to produce parts that are both lighter and stronger than traditional FFF alternatives.
Stratasys also continues to expand its portfolio of additive manufacturing solutions to cater to multiple industries with the introduction of new software and materials. It helps solve real challenges manufacturers face when adopting or scaling additive manufacturing. The company recently launched FDM PA6/66-GF30-FR, a new flame-retardant composite material designed to enable rail and transportation manufacturers to produce certified end-use parts and critical spare parts. The company was also recently recognized for the Eyelid Surgery Training Model, developed in collaboration with Addion. As Europe’s first 3D-printed anatomical eye model for eyelid surgery training, the solution underscores the impact of Stratasys’ Digital Anatomy technology in enabling realistic, repeatable, and scalable medical education. In March, Stratasys’ TrueDent resins received CE marking as a Class IIa medical device, making them Europe’s first high-esthetic, monolithic 3D-printed denture solution to achieve certification in the more than $2 billion market.
The company is also benefiting from rising adoption of additive manufacturing in defense. Its parts-on-demand business, Stratasys Direct, has been selected for the U.S. Department of War’s (DoW) Joint Additive Manufacturing Acceptability (JAMA) IV Pilot Parts Program, a multimillion-dollar initiative to accelerate qualification and deployment of 3D-printed parts across military platforms and systems. In 2025, Stratasys saw double-digit annual revenue growth from aerospace and defense. Stratasys Direct already ships more than 100,000 parts annually to the defense industry, and programs like JAMA will accelerate qualification of parts so organizations can deploy them faster across operational platforms.
AMETEK, through its Specialty Metal Products (SMP) unit, is a leading producer of high-performance metal powders designed for additive manufacturing. It offers a range of alloys and size distributions specific to different additive manufacturing processes, including Laser Powder Bed, Binder Jet and Cold Spray and machines. AME’s most common additive manufacturing powder materials include stainless steel 316L (including A240 grade), stainless steel 304L and Stainless steel 17-4PH. It also offers specialty austenitic and ferritic stainless steels, as well as a selection of high-quality nickel and cobalt alloy powders that are designed specifically for 3D printing applications.
Backed by more than five decades of expertise, the combination of scale, precision and material science enables the company to deliver reliable, high-quality powders that support consistent performance and cost efficiency in additive manufacturing.
In July 2025, AME acquired Faro Technologies, a leading provider of 3D measurement and imaging solutions. Faro’s offerings includes portable measurement arms, laser scanners and trackers, software solutions and comprehensive service offerings serving a diverse range of end markets. This was AMETEK’s largest addition in precision scanning since the acquisition of Creaform in 2013. Creaform is a well-known developer and manufacturer of innovative portable 3D measurement technologies and a provider of 3D engineering services. In October 2024, the company complemented Creaform’s business capabilities with the acquisition of Virtek Vision International, a leading provider of advanced laser-based projection and inspection systems. AME currently carries a Zacks Rank of 2.
ATI provides a full range of capabilities throughout the additive supply chain, from metal powder and material science to the finished part. ATI Additive Manufacturing is one of the select providers with expertise in both Electron Beam Melting and Powder Bed Fusion, designed for highly demanding and precision-critical performance environments. ATI Additive Manufacturing has been at the forefront of Aerospace additive manufacturing since 2014.
Given its extensive powder metals offering, ATI Additive can quickly respond to customers' needs for their additive part demands. Leveraging ATI’s metallurgical leadership, it can also develop new alloys for additive manufacturing on request or address industry challenges. The company continues to increase its production capacity for advanced metallic powders for use in next-generation aerospace products, including additive manufacturing applications.
ATI has commissioned a state-of-the-art facility for additive manufacturing products, bringing online the most advanced large-format, metal additive manufacturing capabilities in the industry. The facility combines design, printing, heat treating, machining and inspection capabilities under one roof. From design to finished product, the company has created a one-stop solution center to address challenges in high-performance markets like aerospace, defense and space. ATI currently carries a Zacks Rank of 2.
Carpenter Technology formed the Carpenter Additive business unit in May 2019. The company has been building its additive capabilities through the acquisitions of LPW Technology Ltd., Puris and CalRAM over the past few years. In late 2019, CRS opened its Emerging Technology Center in Athens, AL, capable of atomizing a range of specialty alloys into metal powder and manufacturing the powder into finished parts using AM technology (3D Metal Printing). The downstream equipment for transforming the initially produced part into a final finished product included the state-of-the-art quick-cooling Hot Isostatic Press system, as well as vacuum heat treating to optimize the material properties of high-value specialty alloy components.
The Carpenter Additive business is one of the world's most versatile producers of spherical, gas-atomized, pre-alloyed metal powders and consolidated powder metallurgy products. The powders meet the unique demands of additive manufacturing, metal injection molding, hot isostatic pressing, near-net shapes, surface enhancement processes and tool steels.
Starting from powder production to manufacturing and finishing parts, the end-to-end capabilities differentiate Carpenter Additive from the rest of the industry. CRS currently carries a Zacks Rank of 2.
Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.
Even though momentum is a popular stock characteristic, it can be tough to define. Debate surrounding which are the best and worst metrics to focus on is lengthy, but the Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.
Below, we take a look at Ametek (AME - Free Report) , which currently has a Momentum Style Score of A. We also discuss some of the main drivers of the Momentum Style Score, like price change and earnings estimate revisions.
It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Ametek currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of "A or B" outperform the market over the following one-month period.
You can see the current list of Zacks #1 Rank Stocks here >>>
Set to Beat the Market?Let's discuss some of the components of the Momentum Style Score for AME that show why this maker of electronic instruments and electromechanical devices shows promise as a solid momentum pick.
Looking at a stock's short-term price activity is a great way to gauge if it has momentum, since this can reflect both the current interest in a stock and if buyers or sellers have the upper hand at the moment. It's also helpful to compare a security to its industry; this can show investors the best companies in a particular area.
For AME, shares are up 4.94% over the past week while the Zacks Electronics - Testing Equipment industry is up 4.1% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 8.41% compares favorably with the industry's 0.13% performance as well.
While any stock can see its price increase, it takes a real winner to consistently beat the market. That is why looking at longer term price metrics -- such as performance over the past three months or year -- can be useful as well. Shares of Ametek have increased 11.3% over the past quarter, and have gained 39.31% in the last year. In comparison, the S&P 500 has only moved 5.95% and 23.52%, respectively.
Investors should also pay attention to AME's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. AME is currently averaging 1,185,550 shares for the last 20 days.
Earnings OutlookThe Zacks Momentum Style Score also takes into account trends in estimate revisions, in addition to price changes. Please note that estimate revision trends remain at the core of Zacks Rank as well. A nice path here can help show promise, and we have recently been seeing that with AME.
Over the past two months, 10 earnings estimates moved higher compared to none lower for the full year. These revisions helped boost AME's consensus estimate, increasing from $8.13 to $8.29 in the past 60 days. Looking at the next fiscal year, 9 estimates have moved upwards while there have been no downward revisions in the same time period.
Bottom LineTaking into account all of these elements, it should come as no surprise that AME is a #2 (Buy) stock with a Momentum Score of A. If you've been searching for a fresh pick that's set to rise in the near-term, make sure to keep Ametek on your short list.
The broader equity markets’ five-day winning streak was punctured yesterday as oil prices surged amid fears that the proposed Iran-Oman truce agreement will prove to be a false dawn yet again. The market rally was largely driven by a solid broad-based earnings performance across sectors and increased optimism about the reopening of the Strait of Hormuz. With the U.S. President also softening his stance on retaliatory attacks, the markets appeared to be on cruise control.
However, markets tumbled on media reports that the draft truce plan would supposedly ban U.S. and Israeli ships from moving through the key passageway, making the peace agreement appear to be far from being guaranteed. As investors employ a wait-and-see approach in a classic example of “backing and filling” in the market, they can benefit from “cash cow” stocks that garner higher returns. However, identifying cash-rich stocks alone does not make for a solid investment proposition unless it is backed by attractive efficiency ratios, such as return on equity (ROE). A high ROE ensures that the company is reinvesting cash at a high rate of return. Micron Technology, Inc. (MU - Free Report) , Arista Networks, Inc. (ANET - Free Report) , Broadcom Inc. (AVGO - Free Report) , Gartner, Inc. (IT - Free Report) and AMETEK, Inc. (AME - Free Report) are some of the stocks with high ROE to profit from.
In order to shortlist stocks that are cash-rich with high ROE, we have added Cash Flow greater than $1 billion and ROE greater than X-Industry as our primary screening parameters. In addition, we have taken a few other criteria into consideration to arrive at a winning strategy.
Price/Cash Flow less than X-Industry: This metric measures how much investors pay for $1 of free cash flow. A lower ratio indicates that investors need to pay less for a better cash flow-generating stock.
Return on Assets (ROA) greater than X-Industry: This metric determines how much profit a company earns for every dollar of assets, which includes cash, accounts receivable, property, equipment, inventory and furniture. The higher the ROA, the better it is for the company.
5-Year EPS Historical Growth greater than X-Industry: This criterion indicates that continued earnings momentum has translated into solid cash strength.
Zacks Rank less than or equal to 2: Zacks Rank #1 (Strong Buy) or 2 (Buy) stocks are known to outperform irrespective of the market environment.
Here are five of the 14 stocks that qualified the screening:
Micron: Headquartered in Idaho, Micron is one of the leading worldwide providers of semiconductor memory solutions. Through global brands, namely Micron, Crucial and Ballistix, it manufactures and markets high-performance memory and storage technologies, including Dynamic Random Access Memory, NAND flash memory, NOR Flash and other technologies. Its solutions are used in leading-edge computing, consumer, networking, mobile, automotive, industrial and data center products.
The company delivered a trailing four-quarter earnings surprise of 21.1%, on average. Micron sports a Zacks Rank #1 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Arista: Santa Clara, CA-based Arista is engaged in providing cloud networking solutions for data centers and cloud computing environments. The company holds a leadership position in 100-gigabit Ethernet switching for the high-speed datacenter segment. It is increasingly gaining market traction in 200- and 400-gig high-performance switching products and remains well-positioned for healthy growth in the data-driven cloud networking business with proactive platforms and predictive operations.
The company has a long-term earnings growth expectation of 26.1%. It delivered a trailing four-quarter earnings surprise of 8.9%, on average. Arista carries a Zacks Rank #2.
Broadcom: Headquartered in San Jose, CA, Broadcom develops a broad range of semiconductor solutions for enterprise and data center networking, home connectivity, set-top boxes, broadband access, telecommunication equipment, smartphones and base stations, data center servers and storage systems, factory automation, power generation and alternative energy systems, and electronic displays.
The company has a long-term earnings growth expectation of 51.2%. It delivered a trailing four-quarter earnings surprise of 2.2%, on average. Broadcom currently carries a Zacks Rank #2.
Gartner: Headquartered in Stamford, CT, Gartner is reportedly the world's leading information technology research and advisory firm. The company offers rich domain expertise and technology-related insight necessary for an informed decision-making process.
Gartner has a long-term earnings growth expectation of 21% and delivered a trailing four-quarter earnings surprise of 13.5%, on average. Gartner sports a Zacks Rank #1.
AMETEK: Located in Berwyn, PA, AMETEK is one of the leading manufacturers of electronic appliances and electromechanical devices. It has more than 120 operating sites worldwide. The company operates more than 80 sales and service stations in North America, Europe, Asia and South America to support these operations.
The company has a long-term earnings growth expectation of 9.4%. It delivered a trailing four-quarter earnings surprise of 4.9%, on average. AMETEK carries a Zacks Rank #2.
Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- The Board of Directors of AMETEK, Inc. (NYSE: AME) declared a regular quarterly dividend of $0.34 per share for the third quarter ending September 30, 2026.
This third quarter dividend is payable September 30, 2026 to shareholders of record as of September 15, 2026.
Corporate Profile:
AMETEK (NYSE: AME) is a leading global provider of industrial technology solutions serving a diverse set of attractive niche markets with annual sales of approximately $7.5 billion. The AMETEK Growth Model integrates the Four Growth Strategies - Operational Excellence, Technology Innovation, Global and Market Expansion, and Strategic Acquisitions - with a disciplined focus on cash generation and capital deployment. AMETEK's objective is double-digit percentage growth in earnings per share over the business cycle and a superior return on total capital. Founded in 1930, AMETEK has been listed on the NYSE for over 95 years and is a component of the S&P 500. For more information, visit www.ametek.com.
Contact:
Kevin Coleman
Vice President, Investor Relations and Treasurer
[email protected]
Phone: 610.889.5247
On August 05, 2026, we conducted a DCF analysis for AMETEK Inc (AME), which has shown notable price performance over the past year. The stock has appreciated si
3 Picks-and-Shovels Stocks Powering the Humanoid Robotics BuildoutAMETEK NYSE: AME reported record second-quarter results for 2026, with double-digit organic sales growth, sharply higher orders, margin expansion and free-cash-flow growth. The company also raised its full-year sales and earnings outlook, citing a strong first half and favorable demand trends across its portfolio.
Second-quarter sales rose 15% year over year to a record $2.04 billion. Organic sales increased 10%, acquisitions contributed 5 percentage points of growth, and foreign currency had no impact. Diluted adjusted earnings per share increased 17% to a record $2.09, exceeding the company’s prior guidance range of $1.96 to $2.00 per share.
Get AMETEK alerts:
Industrials Shine As Ametek, Cintas, Eaton Trade At New Highs“AMETEK delivered fantastic results in Q2 with double-digit organic sales growth, excellent orders growth, strong core margin expansion, outstanding cash flow generation, and record earnings ahead of our expectations,” Chairman and Chief Executive Officer David Zapico said on the call.
Orders and Backlog Reach Records Orders increased 28% to a record $2.3 billion, including 25% organic orders growth. The company ended the quarter with a record backlog of $4.11 billion, up about 21% from the end of 2025, according to Zapico. AMETEK reported a quarterly book-to-bill ratio of 1.12, with both operating groups posting positive book-to-bill.
Zapico said June was the company’s strongest month for orders during the quarter and an all-time monthly record. He added that July orders were also “very good.” Approximately 80% of the backlog is expected to ship within the next 12 months, while the company has begun filling demand into 2027.
Management attributed the order momentum to investments in semiconductor manufacturing, power infrastructure, aerospace and defense, energy-related markets, medical technology and automation. Zapico described the demand environment as the early stages of a multi-year infrastructure buildout, while noting that orders can have a somewhat lumpy cadence.
Segment Performance and Margins The Electronic Instruments Group, or EIG, generated second-quarter sales of $1.32 billion, up 14% from a year earlier. Organic sales grew 7%, while acquisitions added 7 percentage points. Overall EIG orders increased 23%, including 20% organic growth. Core operating margins were 30.1%, up 40 basis points from the prior-year period.
EIG experienced broad-based growth across process instrumentation, aerospace and power businesses. Zapico identified semiconductor demand as a particularly notable contributor within the segment, including demand for precision optics and metrology products used in advanced semiconductor manufacturing.
The Electromechanical Group, or EMG, reported record sales of $723 million, up 17%, with organic sales rising 15% and acquisitions contributing about 2 percentage points. EMG organic orders rose 35%. Operating income increased 32% to a record $191 million, while core operating margins expanded 290 basis points to 26.2%.
Zapico said EMG’s results reflected balanced sales growth across aerospace, defense, medical technology and automation. He highlighted strong orders at Paragon Medical, driven by new design wins in orthopedics, drug-delivery systems and engineered medical components. Management also cited improving life-sciences demand within its automation business.
At the consolidated level, operating income increased 18% to $544 million, while operating margins rose 60 basis points to 26.6%. Core margins expanded 110 basis points to 27.1%. Zapico said the improvement reflected approximately 40% incremental margins, productivity gains and pricing that more than offset inflation and tariffs. He added that there were no tariff refunds affecting quarterly margins.
Cash Flow, Capital Deployment and Acquisitions AMETEK generated operating cash flow of $484 million, up 35% year over year. Free cash flow rose 37% to $452 million, representing 111% conversion of net income. Operating working capital improved to 16.4% of sales from 18.6% a year earlier, aided by inventory discipline and better inventory turns.
Executive Vice President and Chief Financial Officer Dalip Puri said the company expects full-year free-cash-flow conversion of 110% to 115% of net income. AMETEK expects capital expenditures of approximately $160 million in 2026, or about 2% of sales. Zapico said roughly two-thirds of projected capital spending is growth-oriented.
Total debt at June 30 was $2 billion, down from $2.3 billion at the end of 2025, while cash and equivalents totaled $495 million. The company renewed and expanded its revolving credit facility to $3.5 billion, with maturity extended to June 2031.
AMETEK continues to expect its $5 billion acquisition of Indicor Instrumentation to close in the second half of 2026. Puri said the company expects to retain approximately $2.5 billion of cash and available credit facilities after closing. Zapico said management has become increasingly confident in the expected 10% to 12% cost synergies from Indicor, citing opportunities in global sourcing, shared services, facilities and international operations.
The company also said its integration of FARO Technologies is proceeding as planned. Zapico said FARO is expected to offer substantial margin upside over the next six to 12 months and will be included in core margins after AMETEK reaches one year of ownership during the current quarter.
Raised 2026 Outlook For full-year 2026, AMETEK now expects total sales growth of approximately 10%, with organic sales growth in the mid- to high-single-digit range. Adjusted diluted earnings per share are forecast at $8.20 to $8.30, representing growth of 10% to 12% from 2025 and above the company’s previous outlook of $7.94 to $8.14 per share.
For the third quarter, AMETEK expects total sales growth in the high-single digits and adjusted earnings of $2.08 to $2.10 per share, up 10% to 11% from the prior-year period.
Zapico said the company expects continued demand from AI-related semiconductor and power infrastructure investments, commercial aerospace, defense modernization, medical technology and automation. He said that data centers themselves remain a relatively small portion of AMETEK’s business, but related semiconductor, power-grid and infrastructure opportunities are broader. Combined with defense modernization, commercial aerospace and power infrastructure, these themes account for about half of AMETEK’s business, he said.
About AMETEK (NYSE:AME)AMETEK, Inc is a global manufacturer of electronic instruments and electromechanical devices that serves a broad range of industries. Headquartered in Berwyn, Pennsylvania, the company designs and produces precision instruments, electronic measurement devices, specialty sensors, and electric motors and motion control systems. Its product portfolio includes analytical and monitoring instruments, calibration equipment, power supplies, embedded electronics, and industrial motors and drives used for critical applications.
The company operates through two primary business platforms — an electronic instruments group focused on analytical, test and measurement and sensor products, and an electromechanical group that supplies motors, actuators, and related power and motion solutions.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in AMETEK Right Now?Before you consider AMETEK, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AMETEK wasn't on the list.
While AMETEK currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
AMETEK, Inc. (AME) Q2 2026 Earnings Call August 4, 2026 8:30 AM EDT
Company Participants
Kevin Coleman - VP of Investor Relations & Treasurer
David Zapico - Chairman of the Board & CEO
Dalip Puri - Executive VP & CFO
Conference Call Participants
Deane Dray - RBC Capital Markets, Research Division
Matt Summerville - D.A. Davidson & Co., Research Division
Nicole DeBlase - Deutsche Bank AG, Research Division
Daniel DiCicco - BMO Capital Markets Equity Research
Scott Graham - Seaport Research Partners
Christopher Grenga - TD Cowen, Research Division
Andrew Obin - BofA Securities, Research Division
Christopher Glynn - Oppenheimer & Co. Inc., Research Division
Andrew Kaplowitz - Citigroup Inc., Research Division
Presentation
Operator
Good day, and thank you for standing by. Welcome to the Q2 2026 AMETEK Earnings Conference Call. [Operator Instructions] Please be advised that today's conference call is being recorded. I would now like to hand the conference over to your first speaker today, Kevin Coleman, Vice President, Investor Relations and Treasurer. Please go ahead.
Kevin Coleman
VP of Investor Relations & Treasurer
Thank you, Stephanie. Good morning, and welcome to AMETEK's Second Quarter 2026 Earnings Conference Call. Joining me today are Dave Zapico, Chairman and Chief Executive Officer; and Dalip Puri, Executive Vice President and Chief Financial Officer.
During the course of today's call, we will be making forward-looking statements, which are subject to change based on various risk factors and uncertainties that may cause actual results to differ significantly from expectations. A detailed discussion of the risks and uncertainties that may affect our future results is contained in AMETEK's filings with the SEC. AMETEK disclaims any intention or obligation to update or revise any forward-looking statements.
Any references made on this call to historical results will be on an adjusted basis, excluding after-tax acquisition-related intangible amortization and excluding acquisition-related costs. Reconciliations between GAAP and adjusted
Ametek (AME - Free Report) reported $2.04 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 15%. EPS of $2.09 for the same period compares to $1.78 a year ago.
The reported revenue represents a surprise of +4.5% over the Zacks Consensus Estimate of $1.96 billion. With the consensus EPS estimate being $1.99, the EPS surprise was +5.03%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Ametek performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Net Sales- Electronic Instruments: $1.32 billion compared to the $1.28 billion average estimate based on four analysts. The reported number represents a change of +13.9% year over year.Net Sales- Electro mechanical: $723.24 million versus $670.49 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +16.9% change.Operating Income- Electronic Instruments: $369.72 million compared to the $388.27 million average estimate based on four analysts.Operating Income- Corporate administrative expenses: $-30.85 million versus the four-analyst average estimate of $-29.61 million.Operating Income- Electromechanical: $189.32 million versus $167.76 million estimated by four analysts on average.View all Key Company Metrics for Ametek here>>>
Shares of Ametek have returned +2.8% over the past month versus the Zacks S&P 500 composite's +1.7% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Ametek (AME - Free Report) came out with quarterly earnings of $2.09 per share, beating the Zacks Consensus Estimate of $1.99 per share. This compares to earnings of $1.78 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +5.03%. A quarter ago, it was expected that this maker of electronic instruments and electromechanical devices would post earnings of $1.9 per share when it actually produced earnings of $1.97, delivering a surprise of +3.68%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Ametek, which belongs to the Zacks Electronics - Testing Equipment industry, posted revenues of $2.04 billion for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 4.50%. This compares to year-ago revenues of $1.78 billion. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Ametek shares have added about 18.7% since the beginning of the year versus the S&P 500's gain of 11%.
What's Next for Ametek?While Ametek has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Ametek was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $2.04 on $2 billion in revenues for the coming quarter and $8.14 on $8.01 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Electronics - Testing Equipment is currently in the top 9% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Cognex Corporation (CGNX - Free Report) , is yet to report results for the quarter ended June 2026. The results are expected to be released on August 5.
This company is expected to post quarterly earnings of $0.42 per share in its upcoming report, which represents a year-over-year change of +68%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Cognex Corporation's revenues are expected to be $293.24 million, up 17.7% from the year-ago quarter.
, /PRNewswire/ -- AMETEK, Inc. (NYSE: AME) today announced its financial results for the second quarter ended June 30, 2026.
AMETEK's second quarter 2026 sales were a record $2.04 billion, a 15% increase over the second quarter of 2025. On a GAAP basis, second quarter earnings were a record $1.77 per diluted share. Adjusted earnings in the quarter were a record $2.09 per diluted share, up 17% from the second quarter of 2025. Adjusted earnings adds back non-cash, after-tax, acquisition-related intangible amortization, financing fees and integration costs of $0.32 per diluted share.
GAAP operating income was a record $528.2 million. Adjusted operating income increased 18% to a record $544.4 million and operating margins were 26.6% in the quarter, up 60 basis points from the prior year. Operating cash flow in the quarter was up 35% to $483.7 million and free cash flow to net income conversion was 111%. A reconciliation of reported GAAP results to adjusted results is included in the financial tables accompanying this release and on the AMETEK website.
"AMETEK delivered superb results in the second quarter. Strong organic sales growth, contributions from recent acquisitions, and outstanding operating performance led to high-teens earnings growth, excellent 110 basis points of core margin expansion and record operating performance," stated David A. Zapico, AMETEK Chairman and Chief Executive Officer. "Notably, for the second quarter in a row, orders were exceptional, growing 28% in the quarter."
Electronic Instruments Group (EIG)
EIG sales in the second quarter were $1.32 billion, an increase of 14% over the same period in 2025. On a GAAP basis, EIG's second quarter operating income was $369.8 million. On an adjusted basis, EIG's operating income was up 12% to $384.7 million.
"EIG generated outstanding results in the second quarter with mid-teens sales growth, sizeable orders growth and excellent operating performance," commented Mr. Zapico. "Sales growth in the quarter was balanced between organic growth and contributions from recent acquisitions, with excellent orders growth highlighted by our semiconductor and commercial aerospace markets. Further, EIG's strong operating performance drove core margins up 40 basis points to 30.1%."
Electromechanical Group (EMG)
EMG sales in the second quarter were a record $723.2 million, up 17% from the second quarter of 2025. In the quarter, EMG's GAAP operating income was $189.3 million. On an adjusted basis, EMG's operating income increased 32% to a record $190.5 million and operating income margins were 26.3%.
"EMG delivered exceptional results in the second quarter. Strong organic sales growth resulted in sizeable profit growth and 290 basis points of core margin expansion," noted Mr. Zapico. "Orders growth was also outstanding and broad-based in the quarter with notable strength in medtech, defense and automation markets."
Third Quarter and Full Year 2026 Outlook
"Our businesses performed exceptionally well in the second quarter highlighting the strength of the AMETEK Growth Model, the quality of our business and the attractiveness of our markets. Our broad-based sales and orders growth reflects our unique position as a mission critical provider of highly differentiated solutions supporting strong secular growth markets including the global infrastructure build-out," added Mr. Zapico.
"For 2026, we now expect overall sales to be up approximately 10% versus 2025. Adjusted earnings per diluted share are now expected to be in the range of $8.20 to $8.30, up 10% to 12% over the comparable basis for 2025. This is an increase from our prior guidance range of $7.94 to $8.14 per diluted share reflecting our strong underlying performance and outlook for the balance of the year," he added.
"For the third quarter of 2026, overall sales are expected to be up high single digits on a percentage basis compared to the third quarter of 2025. Adjusted earnings in the quarter are anticipated to be in the range of $2.08 to $2.10 per share, up 10% to 11% compared to the third quarter of 2025," concluded Mr. Zapico.
Conference Call
AMETEK will webcast its second quarter 2026 investor conference call on Tuesday, August 4, 2026, beginning at 8:30 AM ET. The live audio webcast will be available and later archived in the Investors section of www.ametek.com.
Corporate Profile
AMETEK (NYSE: AME) is a leading global provider of industrial technology solutions serving a diverse set of attractive niche markets with annual sales of approximately $8.0 billion. The AMETEK Growth Model integrates the Four Growth Strategies - Operational Excellence, Technology Innovation, Global and Market Expansion, and Strategic Acquisitions - with a disciplined focus on cash generation and capital deployment. AMETEK's objective is double-digit percentage growth in earnings per share over the business cycle and a superior return on total capital. Founded in 1930, AMETEK has been listed on the NYSE for over 95 years and is a component of the S&P 500. For more information, visit www.ametek.com.
Forward-looking Information
Statements in this news release relating to future events, such as AMETEK's expected business and financial performance, are "forward-looking statements." Forward-looking statements are subject to various factors and uncertainties that may cause actual results to differ materially from expectations. These factors and uncertainties include risks related to AMETEK's ability to consummate and successfully integrate future acquisitions; risks with international sales and operations, including supply chain disruptions, tariffs, trade disputes and currency conditions; AMETEK's ability to successfully develop new products, open new facilities or transfer product lines; the price and availability of raw materials; compliance with government regulations, including environmental regulations; changes in the competitive environment or the effects of competition in our markets; the ability to maintain adequate liquidity and financing sources; and general economic conditions affecting the industries we serve. A detailed discussion of these and other factors that may affect our future results is contained in AMETEK's filings with the U.S. Securities and Exchange Commission, including its most recent reports on Forms 10-K, 10-Q and 8-K. AMETEK disclaims any intention or obligation to update or revise any forward-looking statements.
Contact:
Kevin Coleman
Vice President, Investor Relations and Treasurer
[email protected]
Phone: 610.889.5247
AMETEK, Inc.
Consolidated Statement of Income
(In thousands, except per share amounts)
(Unaudited)
Three Months Ended
June 30,
Six Months Ended
June 30,
2026
2025
2026
2025
Net sales
$ 2,044,397
$ 1,778,056
$ 3,972,834
$ 3,510,027
Cost of sales
1,309,356
1,142,167
2,520,234
2,249,138
Selling, general and administrative
206,848
174,263
409,471
344,434
Total operating expenses
1,516,204
1,316,430
2,929,705
2,593,572
Operating income
528,193
461,626
1,043,129
916,455
Interest expense
(30,101)
(16,857)
(51,010)
(35,850)
Other (expense) income, net
(5,720)
(2,600)
(6,767)
(4,214)
Income before income taxes
492,372
442,169
985,352
876,391
Provision for income taxes
85,476
83,802
179,099
166,266
Net income
$ 406,896
$ 358,367
$ 806,253
$ 710,125
Diluted earnings per share
$ 1.77
$ 1.55
$ 3.51
$ 3.07
Basic earnings per share
$ 1.78
$ 1.55
$ 3.52
$ 3.08
Weighted average common shares
outstanding:
Diluted shares
229,855
231,472
229,845
231,507
Basic shares
229,086
230,818
228,994
230,743
Dividends per share
$ 0.34
$ 0.31
$ 0.68
$ 0.62
AMETEK, Inc.
Information by Business Segment
(In thousands)
(Unaudited)
Three Months Ended
June 30,
Six Months Ended
June 30,
2026
2025
2026
2025
Net sales:
Electronic Instruments
$ 1,321,153
$ 1,159,571
$ 2,585,689
$ 2,303,244
Electromechanical
723,244
618,485
1,387,145
1,206,783
Consolidated net sales
$ 2,044,397
$ 1,778,056
$ 3,972,834
$ 3,510,027
Operating income:
Segment operating income:
Electronic Instruments
$ 369,722
$ 344,428
$ 743,660
$ 698,478
Electromechanical
189,317
143,888
360,083
272,606
Total segment operating income
559,039
488,316
1,103,743
971,084
Corporate administrative expenses
(30,846)
(26,690)
(60,614)
(54,629)
Consolidated operating income
$ 528,193
$ 461,626
$ 1,043,129
$ 916,455
AMETEK, Inc.
Condensed Consolidated Balance Sheet
(In thousands)
June 30,
December 31,
2026
2025
(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents
$ 495,446
$ 457,951
Receivables, net
1,170,497
1,119,257
Inventories, net
1,195,383
1,106,405
Other current assets
365,475
336,229
Total current assets
3,226,801
3,019,842
Property, plant and equipment, net
850,173
855,215
Right of use assets, net
259,308
273,142
Goodwill
7,418,304
7,170,770
Other intangibles, investments and other assets
4,840,127
4,748,574
Total assets
$ 16,594,713
$ 16,067,543
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Short-term borrowings and current portion of long-term debt, net
$ 980,633
$ 1,208,975
Accounts payable and accruals
1,677,965
1,633,777
Total current liabilities
2,658,598
2,842,752
Long-term debt, net
1,055,541
1,074,334
Deferred income taxes and other long-term liabilities
1,619,811
1,521,671
Stockholders' equity
11,260,763
10,628,786
Total liabilities and stockholders' equity
$ 16,594,713
$ 16,067,543
AMETEK, Inc.
Reconciliations of GAAP to Non-GAAP Financial Measures
(In thousands, except per share amounts)
(Unaudited)
Three Months Ended June 30,
2026
2025
EIG Segment operating income (GAAP)
$ 369,722
$ 344,428
Acquisition-related costs(1)
14,996
—
Adjusted EIG Segment operating income (Non-GAAP)
$ 384,718
$ 344,428
EMG Segment operating income (GAAP)
$ 189,317
$ 143,888
Acquisition-related costs(1)
1,208
—
Adjusted EMG Segment operating income (Non-GAAP)
$ 190,525
$ 143,888
Operating income (GAAP)
$ 528,193
$ 461,626
Acquisition-related costs(1)
16,204
—
Adjusted Operating income (Non-GAAP)
$ 544,397
$ 461,626
Interest expense (GAAP)
$ 30,101
$ 16,857
Acquisition-related costs(1)
(10,006)
—
Adjusted interest expense (non-GAAP)
$ 20,095
$ 16,857
Diluted earnings per share (GAAP)
$ 1.77
$ 1.55
Acquisition-related costs(1)
0.11
—
Income tax benefit on acquisition-related costs(1)
(0.02)
—
Pretax amortization of acquisition-related intangible assets
0.30
0.31
Income tax benefit on amortization of acquisition-related intangible assets
(0.07)
(0.08)
Rounding
—
—
Adjusted Diluted earnings per share (Non-GAAP)
$ 2.09
$ 1.78
Cash provided by operating activities (GAAP)
$ 483,693
$ 359,089
Deduct: Capital expenditures
(32,012)
(29,269)
Free cash flow (Non-GAAP)
$ 451,681
$ 329,820
Free cash flow conversion (Non-GAAP)
111 %
92 %
(1)
-
Acquisition-related costs comprise integration costs in Cost of Sales and one-time Indicor bridge financing fees in interest expense.
AMETEK, Inc.
Reconciliations of GAAP to Non-GAAP Financial Measures
(In thousands, except per share amounts)
(Unaudited)
Three Months Ended
June 30,
2026
2025
Change
EIG Segment operating margin (GAAP)
28.0 %
29.7 %
Acquisition-related costs(1)
1.1 %
— %
Adjusted EIG Segment operating margin (Non-GAAP)
29.1 %
29.7 %
Dilutive impact of acquisitions and foreign exchange(2)
Dilutive impact of acquisitions and foreign exchange(2)
0.5 %
— %
Adjusted core operating income margin (Non-GAAP)
27.1 %
26.0 %
1.1 %
(1)
-
Acquisition-related costs comprise integration costs in Cost of Sales and one-time Indicor bridge financing fees in interest expense.
(2)
-
Operating income margins adjusted for dilutive impact from acquisitions completed in the last twelve months and the foreign exchange gain or loss.
AMETEK, Inc.
Reconciliations of GAAP to Non-GAAP Financial Measures
(Unaudited)
Forecasted Diluted Earnings Per Share
Three Months Ended
Year Ended
September 30, 2026
December 31,2026
Low
High
Low
High
Diluted earnings per share (GAAP)
$ 1.85
$ 1.87
$ 7.19
$ 7.29
Pretax amortization of acquisition-related intangible
assets
0.31
0.31
1.21
1.21
Income tax benefit on amortization of acquisition-related
intangible assets
(0.08)
(0.08)
(0.30)
(0.30)
Acquisition-related costs(3)
—
—
0.12
0.12
Income tax benefit on acquisition-related costs(3)
—
—
(0.02)
(0.02)
Adjusted Diluted earnings per share (Non-GAAP)
$ 2.08
$ 2.10
$ 8.20
$ 8.30
(3)
-
In providing forward-looking guidance for quarterly and full-year GAAP and non-GAAP measures, the Company has not included adjustments, such as acquisition-related costs, whose timing and/or magnitude are contingent on future events. Acquisition-related costs reflected in the table above are actual June 30, 2026 year-to-date adjustments.
Use of Non-GAAP Financial Information
The Company supplements its consolidated financial statements presented on a U.S. generally accepted accounting principles ("GAAP") basis with certain non-GAAP financial information to provide investors with greater insight, increased transparency and allow for a more comprehensive understanding of the information used by management in its financial and operational decision-making. Reconciliation of non-GAAP measures to their most directly comparable GAAP measures are included in the accompanying financial tables. These non-GAAP financial measures should be considered in addition to, and not as a replacement for, or superior to, the comparable GAAP measure, and may not be comparable to similarly titled measures reported by other companies.
The non-GAAP financial measures referenced in this press release include adjusted operating income, adjusted operating margin, and adjusted earnings per share. These measures are adjusted to exclude items that management does not consider indicative of AMETEK's ongoing operational performance, such as after-tax acquisition-related intangible amortization, one-time acquisition-related costs (including transaction related costs, purchase accounting adjustments, and integration related costs).
In providing forward-looking guidance for quarterly and full-year GAAP and non-GAAP measures, the Company has not included adjustments, such as acquisition-related costs, whose timing and/or magnitude are contingent on future events.
The Company believes that these measures provide useful information to investors by reflecting additional ways of viewing AMETEK's operations that, when reconciled to the comparable GAAP measure, helps our investors to better understand the long-term profitability trends of our business, and facilitates easier comparisons of our profitability to prior and future periods and to our peers.
Analysts on Wall Street project that Ametek (AME - Free Report) will announce quarterly earnings of $1.99 per share in its forthcoming report, representing an increase of 11.8% year over year. Revenues are projected to reach $1.96 billion, increasing 10% from the same quarter last year.
The consensus EPS estimate for the quarter has been revised 0.5% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
That said, let's delve into the average estimates of some Ametek metrics that Wall Street analysts commonly model and monitor.
Analysts expect 'Net Sales- Electronic Instruments' to come in at $1.28 billion. The estimate suggests a change of +10.5% year over year.
Analysts forecast 'Net Sales- Electro mechanical' to reach $670.49 million. The estimate suggests a change of +8.4% year over year.
The consensus among analysts is that 'Operating Income- Electronic Instruments' will reach $388.27 million. The estimate is in contrast to the year-ago figure of $344.43 million.
Based on the collective assessment of analysts, 'Operating Income- Electromechanical' should arrive at $167.76 million. The estimate compares to the year-ago value of $143.89 million.
View all Key Company Metrics for Ametek here>>>
Over the past month, Ametek shares have recorded returns of -0.8% versus the Zacks S&P 500 composite's -1.5% change. Based on its Zacks Rank #2 (Buy), AME will likely outperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Wall Street expects a year-over-year increase in earnings on higher revenues when Ametek (AME - Free Report) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.
The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on August 4. On the other hand, if they miss, the stock may move lower.
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.
Zacks Consensus EstimateThis maker of electronic instruments and electromechanical devices is expected to post quarterly earnings of $1.99 per share in its upcoming report, which represents a year-over-year change of +11.8%.
Revenues are expected to be $1.96 billion, up 10% from the year-ago quarter.
Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 0.49% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.
Price, Consensus and EPS Surprise
Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Ametek?For Ametek, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +0.39%.
On the other hand, the stock currently carries a Zacks Rank of #2.
So, this combination indicates that Ametek will most likely beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Ametek would post earnings of $1.9 per share when it actually produced earnings of $1.97, delivering a surprise of +3.68%.
Over the last four quarters, the company has beaten consensus EPS estimates four times.
Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Ametek appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
The Zacks Electronics – Testing Equipment industry has been benefiting from the rapid build-out of AI infrastructure, which is increasing demand for semiconductor manufacturing and validation equipment. Testing solutions are becoming increasingly critical for wafer fabrication, chip inspection, embedded computing validation and hardware verification. The build-out of hyperscale data centers and power infrastructure is increasing demand for electrical testing, power validation and hardware-in-the-loop simulation. Factories and logistics facilities are investing in greater automation, increasing demand for machine vision, barcode reading and automated inspection systems. The launch of AI-powered testing and inspection platforms that improve speed, accuracy and productivity has noteworthy development. Industry players like AMETEK (AME - Free Report) and Fortive (FTV - Free Report) are benefiting from this trend. However, supply chain constraints and component inflation are headwinds for industry players.
Industry Description The Zacks Electronics – Testing Equipment industry comprises companies offering advanced instruments, electronic testing equipment solutions, thermal management systems, electrical connectors, motors and various test solutions. The major end markets served by this industry are consumer, automobile, industrial, aerospace and defense, healthcare, semiconductors and communications, to name a few. Industry participants have been making technological advancements to gain traction among semiconductors, vehicles, machinery, smartphones and medical device manufacturers, who are constantly increasing their spending on electronic components.
4 Trends Shaping the Future of Electronics - Testing Equipment Industry Solid Adoption of Motion Control & Test Systems is Positive: The rising utilization of precision motion-control solutions and automatic test systems in motion-control devices and testing products, particularly in the aerospace, automation, medical and military markets, is an upside. Commercial motor and autonomous vehicles will likely continue to hike the demand for vehicle-tracking systems, fleet-management solutions and other private fleet applications, which are part of the industry’s key offerings.
Secular Growth, Niche Strength and Sustainability-Driven Demand Aids Growth: Secular growth is driven by exposure to long-term themes like automation, healthcare, aerospace, semiconductors and energy transition. Industry players operate in niche, mission-critical segments where products are essential to performance and safety. This supports strong pricing power, customer attachment and consistently high margins compared to broader industrial peers. Sustainability and energy transition trends are creating new demand for products that improve efficiency, reduce emissions and support renewable energy adoption, providing an additional long-term growth driver.
Recurring Revenues Boost Free Cash Flow Generation Ability: A meaningful portion of revenue comes from recurring streams such as aftermarket services, calibration, maintenance and spares. This improves earnings visibility and reduces volatility across cycles. Asset-light business models require relatively low capital expenditure, resulting in high free cash flow conversion. This supports shareholder returns, reinvestment and acquisition strategies.
Macroeconomic Headwinds Pose Concerns: Due to the challenging macroeconomic scenario, enterprises are reluctant to sign multi-year deals worldwide. The industry is seeing supply chain volatility, along with the negative impact of tariffs. These trends do not bode well for the industry participants.
Zacks Industry Rank Indicates Bright Prospects The Zacks Electronics – Testing Equipment industry is housed within the broader Zacks Computer and Technology sector. It carries a Zacks Industry Rank #28 at present, which places it in the top 11% of more than 250 Zacks industries.
The group’s Zacks Industry Rank, the average of the Zacks Rank of all the member stocks, indicates bullish near-term prospects. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than two to one.
The industry’s position in the top 50% of the Zacks-ranked industries is a result of a positive earnings outlook for the constituent companies in aggregate. Looking at the aggregate earnings estimate revisions, it appears that analysts are optimistic about this group’s earnings growth potential. The industry’s earnings estimates for 2026 have moved north by 10.8% since July 31, 2025.
Given the bullish scenario, there are a number of stocks currently worth watching. But before we present those stocks, let us look at the industry’s recent stock-market performance and the valuation picture.
Industry Outperforms S&P 500 & Sector The Zacks Electronics – Testing Equipment industry has outperformed the S&P 500 and the broader sector over the past year. The industry has climbed 31.6% over this period against the S&P 500’s appreciation of 21.2% and the broader sector’s return of 27.4%.
One-Year Price Performance
Industry's Current Valuation Based on the forward 12-month price-to-earnings ratio (P/E), a commonly used multiple for valuing the Electronics – Testing Equipment stocks, the industry is currently trading at 25.49X, higher than the S&P 500’s 20.74X and the sector’s 25.56X.
Over the past five years, the industry has traded as high as 30.91X and as low as 19.23X, with a median of 23.83X, as the chart below shows.
Forward 12-Month P/E Ratio
2 Testing Equipment Stocks to Buy AMETEK: This Zacks Rank #2 (Buy) company is benefiting from strong order growth, record backlog and acquisitions. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
AMETEK’s order momentum increased in the first quarter of 2026. Total orders were $2.2 billion, up 23% year over year, lifting backlog to a record $3.87 billion. AMETEK continues to supplement organic growth with bolt-on acquisitions in niche markets that extend the portfolio. In April 2026, AMETEK entered into a definitive agreement to acquire First Aviation Services, a defense and aviation MRO provider with about $80 million of annual sales that will join EMG, adding further defense aftermarket exposure. The company acquired LKC Technologies in January 2026 for $209.6 million of cash, adding ophthalmic diagnostics capabilities within EIG.
AMETEK expects 2026 sales to increase high single digits. The company expects earnings between $7.94 and $8.14 per share, suggesting 7-10% year-over-year growth.
The Zacks Consensus Estimate for 2026 earnings has increased by a penny to $8.14 per share over the past 30 days, indicating year-over-year growth of 9.56%. Shares of AMETEK have climbed 14.6% year to date.
Price & Consensus: AME
Fortive: This Zacks Rank #2 company is benefiting from steady demand across Intelligent Operating Solutions and Advanced Healthcare Solutions. Fortive's “Fortive Accelerated” strategy is gaining traction. The company reported more than 5% core revenue growth in the first quarter of 2026, with growth accelerating across both operating segments. The company highlighted continued momentum in innovation, commercial execution and recurring customer value initiatives, while reaffirming confidence in its 2026-2027 financial framework.
Fortive is benefiting from the AI infrastructure buildout through its Fluke business. The company is seeing strong customer adoption of its CertiFiber Max data center testing solution, which is also driving sales of complementary products such as power quality, battery testing and calibration equipment.
Fortive expects 2026 adjusted earnings between $2.90 and $3 per share, indicating 9% year-over-year growth at the midpoint. The Zacks Consensus Estimate for 2026 earnings has been revised a penny upward in the past 30 days to $2.97 per share, indicating year-over-year growth of 9.59%. Shares of Fortive have climbed 10.5% year to date.
California Public Employees Retirement System decreased its stake in AMETEK, Inc. (NYSE:AME – Free Report) by 7.0% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 401,034 shares of the technology company’s stock after selling 30,304 shares during the quarter. California Public Employees Retirement System owned approximately 0.17% of AMETEK worth $85,966,000 at the end of the most recent quarter.
A number of other institutional investors also recently modified their holdings of the stock. Florida Financial Advisors LLC lifted its holdings in shares of AMETEK by 2.2% during the 4th quarter. Florida Financial Advisors LLC now owns 1,974 shares of the technology company’s stock valued at $406,000 after buying an additional 43 shares during the last quarter. Plato Investment Management Ltd raised its position in AMETEK by 0.4% during the fourth quarter. Plato Investment Management Ltd now owns 10,751 shares of the technology company’s stock valued at $2,218,000 after acquiring an additional 47 shares in the last quarter. Allegiance Financial Group Advisory Services LLC raised its position in AMETEK by 4.0% during the fourth quarter. Allegiance Financial Group Advisory Services LLC now owns 1,254 shares of the technology company’s stock valued at $257,000 after acquiring an additional 48 shares in the last quarter. Washington Trust Advisors Inc. lifted its stake in AMETEK by 6.2% in the fourth quarter. Washington Trust Advisors Inc. now owns 850 shares of the technology company’s stock valued at $175,000 after acquiring an additional 50 shares during the last quarter. Finally, Root Financial Partners LLC grew its position in AMETEK by 18.3% in the first quarter. Root Financial Partners LLC now owns 323 shares of the technology company’s stock worth $69,000 after acquiring an additional 50 shares in the last quarter. Institutional investors and hedge funds own 87.43% of the company’s stock.
AMETEK Trading Down 0.1% AMETEK stock opened at $236.66 on Monday. The company has a quick ratio of 0.72, a current ratio of 1.14 and a debt-to-equity ratio of 0.10. The business has a 50 day moving average price of $231.11 and a two-hundred day moving average price of $226.52. AMETEK, Inc. has a 12 month low of $175.61 and a 12 month high of $244.71. The stock has a market cap of $54.24 billion, a price-to-earnings ratio of 35.75, a price-to-earnings-growth ratio of 3.32 and a beta of 0.99.
AMETEK (NYSE:AME – Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The technology company reported $1.97 earnings per share for the quarter, beating analysts’ consensus estimates of $1.90 by $0.07. AMETEK had a return on equity of 16.63% and a net margin of 20.11%.The company had revenue of $1.93 billion for the quarter, compared to the consensus estimate of $1.91 billion. During the same period in the previous year, the business earned $1.75 earnings per share. The company’s quarterly revenue was up 11.3% on a year-over-year basis. AMETEK has set its FY 2026 guidance at 7.940-8.140 EPS and its Q2 2026 guidance at 1.960-2.000 EPS. As a group, equities analysts forecast that AMETEK, Inc. will post 8.14 EPS for the current year.
AMETEK Dividend Announcement The business also recently declared a quarterly dividend, which was paid on Tuesday, June 30th. Investors of record on Monday, June 15th were given a dividend of $0.34 per share. The ex-dividend date was Monday, June 15th. This represents a $1.36 annualized dividend and a yield of 0.6%. AMETEK’s dividend payout ratio is 20.54%.
Wall Street Analysts Forecast Growth Several research firms recently issued reports on AME. Robert W. Baird set a $244.00 price objective on shares of AMETEK in a research note on Friday, May 1st. Wall Street Zen downgraded shares of AMETEK from a “buy” rating to a “hold” rating in a research report on Sunday, May 10th. Truist Financial raised their target price on AMETEK from $275.00 to $303.00 and gave the company a “buy” rating in a report on Thursday, July 2nd. DA Davidson reiterated a “buy” rating and set a $265.00 price target on shares of AMETEK in a research note on Monday, May 4th. Finally, Royal Bank Of Canada increased their price objective on AMETEK from $259.00 to $260.00 and gave the company an “outperform” rating in a report on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $256.29.
Check Out Our Latest Analysis on AMETEK
AMETEK Company Profile (Free Report)
AMETEK, Inc is a global manufacturer of electronic instruments and electromechanical devices that serves a broad range of industries. Headquartered in Berwyn, Pennsylvania, the company designs and produces precision instruments, electronic measurement devices, specialty sensors, and electric motors and motion control systems. Its product portfolio includes analytical and monitoring instruments, calibration equipment, power supplies, embedded electronics, and industrial motors and drives used for critical applications.
The company operates through two primary business platforms — an electronic instruments group focused on analytical, test and measurement and sensor products, and an electromechanical group that supplies motors, actuators, and related power and motion solutions.
Further Reading Five stocks we like better than AMETEK Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit Shopify’s Quiet AI Strategy Could Be Its Biggest Advantage Yet Why These 3 Nuclear ETFs Are Getting a Fresh Look as AI Power Demand Rises 3 Aerospace Suppliers That Could Benefit as Aircraft Makers Face Bottlenecks Want to see what other hedge funds are holding AME? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AMETEK, Inc. (NYSE:AME – Free Report).
Receive News & Ratings for AMETEK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMETEK and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEiShares Large Cap Max Buffer Mar ETF (BATS:MMAX) CTO Sells $145,100.00 in Stock
NEXT HEADLINE »Saga (LON:SAGA) Insider Mark Watkins Purchases 276 Shares
Ness Ziona, Israel, July 17, 2026 (GLOBE NEWSWIRE) -- QTREX Quantum Ltd. (Nasdaq: QTEX) ("QTREX" or the "Company"), a company focused on advancing Additively Manufactured Electronics (“AME”) for quantum computing infrastructure, today announced that on July 14, 2026, its Board of Directors (the “Board”) appointed Dr. Shlomit Chappel-Ram as an independent director, effective immediately.
Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact - Earnings to be released before market opens on Tuesday, August 4, 2026 -
, /PRNewswire/ -- AMETEK, Inc. (NYSE: AME) will issue its second quarter 2026 earnings release before the market opens on Tuesday, August 4, 2026.
AMETEK will webcast its second quarter 2026 investor conference call on Tuesday, August 4, 2026, beginning at 8:30 AM ET. The live audio webcast can be accessed by clicking on the Events & Presentations link in the "Investors" section of www.ametek.com. A replay of the call will also be archived on the website and will be available until the next quarterly earnings call.
Corporate Profile:
AMETEK (NYSE: AME) is a leading global provider of industrial technology solutions serving a diverse set of attractive niche markets with annual sales of approximately $7.5 billion. The AMETEK Growth Model integrates the Four Growth Strategies - Operational Excellence, Technology Innovation, Global and Market Expansion, and Strategic Acquisitions - with a disciplined focus on cash generation and capital deployment. AMETEK's objective is double-digit percentage growth in earnings per share over the business cycle and a superior return on total capital. Founded in 1930, AMETEK has been listed on the NYSE for over 95 years and is a component of the S&P 500. For more information, visit www.ametek.com.
Contact:
Kevin Coleman
Vice President, Investor Relations and Treasurer
[email protected]
Phone: 610.889.5247
If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Ametek (AME - Free Report) . This company, which is in the Zacks Electronics - Testing Equipment industry, shows potential for another earnings beat.
This maker of electronic instruments and electromechanical devices has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 3.65%.
For the most recent quarter, Ametek was expected to post earnings of $1.9 per share, but it reported $1.97 per share instead, representing a surprise of 3.68%. For the previous quarter, the consensus estimate was $1.94 per share, while it actually produced $2.01 per share, a surprise of 3.61%.
Price and EPS Surprise
With this earnings history in mind, recent estimates have been moving higher for Ametek. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the company is positive, which is a great sign of an earnings beat, especially when you combine this metric with its nice Zacks Rank.
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Ametek currently has an Earnings ESP of +0.39%, which suggests that analysts have recently become bullish on the company's earnings prospects. This positive Earnings ESP when combined with the stock's Zacks Rank #2 (Buy) indicates that another beat is possibly around the corner.
Investors should note, however, that a negative Earnings ESP reading is not indicative of an earnings miss, but a negative value does reduce the predictive power of this metric.
Many companies end up beating the consensus EPS estimate, but that may not be the sole basis for their stocks moving higher. On the other hand, some stocks may hold their ground even if they end up missing the consensus estimate.
Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Nes Ziona, Israel, July 06, 2026 (GLOBE NEWSWIRE) -- QTREX Quantum Ltd. (Nasdaq: QTEX) ("QTREX" or the "Company") a company focused on advancing Additively Manufactured Electronics (“AME”) for quantum computing infrastructure today announced that a U.S. Government lab conducting quantum computing programs is actively operating the Company’s AME system. The operational use places the Company’s technology inside a U.S. federal quantum and advanced-microelectronics development environment, providing the lab with direct access to the unique capabilities enabled by the Company’s AME platform.
The lab is one of the most prominent U.S. government research environments focused on national security, applying advanced science and engineering to help identify, deter, defeat and mitigate threats to the United States and its allies. Within this environment, the lab conducts quantum computing programs focused on moving quantum technologies from experimental research toward practical, measurable and engineered systems. This includes fabrication and characterization, integrated control technologies, mathematical modeling and experimental testing on real-world quantum systems.
As quantum systems advance toward larger and more complex architectures, they require new approaches for manufacturing high-density interconnects, advanced packaging structures, integrated materials, RF/microwave pathways and application-specific electronic components. The operational use of QTREX’s AME system inside this environment positions the Company’s technology directly within the infrastructure layer required to support quantum hardware development.
"The current U.S. administration has made it unequivocally clear that quantum computing and advanced microelectronics are critical, heavily funded national security priorities," said Dagi Ben-Noon, CEO of QTREX. "Having our AME system actively operating inside a federal lab directly aligns QTREX with these massive strategic initiatives and positions us at the heart of the infrastructure required to secure U.S. quantum leadership."
QTREX views this operational deployment as a strategic platform for deeper technical engagement, defined use cases and broader commercial expansion. Amid an accelerating wave of federal investment in sovereign quantum infrastructure, direct exposure to AME capabilities within this national security lab environment paves the way for future application-specific development tailored to sensitive, mission-critical and classified defense applications.
About QTREX Quantum
QTREX Quantum Ltd. (Nasdaq: QTEX) is a technology company focused on advanced connectivity and electronics manufacturing solutions for next-generation hardware markets. Following its acquisition of the AME platform, the Company is developing high-density, thermally optimized quantum connectivity solutions for dilution cryostats and advancing AME applications for defense, aerospace, missile, space, and other mission-critical environments. The Company also continues to advance its medical technology portfolio, including respiratory support and blood monitoring platforms, while actively working to monetize certain parts of the medical business.
For more information, please visit: QTREX
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses that having its AME system actively operating inside a federal lab directly aligns QTREX with these strategic initiatives, positioning it at the heart of the infrastructure required to secure U.S. quantum leadership, its view that this operational deployment is a strategic platform for deeper technical engagement, defined use cases and broader commercial expansion, an accelerating wave of federal investment in sovereign quantum infrastructure, direct exposure to AME capabilities within this national security lab environment paves the way for future application-specific development tailored to sensitive, mission-critical and classified defense applications. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements. More detailed information about the risks and uncertainties affecting the Company is contained under “Risk Factors” in the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission.
Company Contact
QTREX Quantum
Email: [email protected]
Phone: +972-9-9664487
On June 17, 2026, we present a DCF analysis for AMETEK Inc (AME), a company that has shown notable price performance with a year-to-date increase of 13.3% and a
, /PRNewswire/ -- AMETEK, Inc. (NYSE: AME) today announced that it has entered into a definitive agreement to acquire First Aviation Services, a leading provider of highly engineered, mission-critical defense and aviation maintenance, repair and overhaul (MRO) services and a manufacturer of related proprietary components.
First Aviation's MRO capabilities include advanced electronics, rotor blades and assemblies, propellers, landing gear, and flight controls. In addition, First Aviation specializes in designing, engineering, and manufacturing critical parts across a wide range of defense and aviation platforms.
"First Aviation is a strong strategic fit with our MRO platform, providing attractive market expansion opportunities and broadening the scope of our component MRO services," said David A. Zapico, AMETEK Chairman and Chief Executive Officer. "Their proprietary products and services further broaden our differentiated products serving mission critical applications. We look forward to leveraging our respective operating, engineering and distribution strengths to continue to grow our combined capabilities."
First Aviation Services has annual sales of approximately $80 million and operates six centers of excellence throughout the U.S. The transaction is subject to customary closing conditions, including applicable regulatory approvals.
Corporate Profile
AMETEK (NYSE: AME) is a leading global provider of industrial technology solutions serving a diverse set of attractive niche markets with annual sales of approximately $7.5 billion. The AMETEK Growth Model integrates the Four Growth Strategies - Operational Excellence, Technology Innovation, Global and Market Expansion, and Strategic Acquisitions - with a disciplined focus on cash generation and capital deployment. AMETEK's objective is double-digit percentage growth in earnings per share over the business cycle and a superior return on total capital. Founded in 1930, AMETEK has been listed on the NYSE for over 95 years and is a component of the S&P 500. For more information, visit www.ametek.com.
Contact:
Kevin Coleman
Vice President, Investor Relations and Treasurer
[email protected]
Phone: 610-889-5247
Ametek (AME) came out with quarterly earnings of $1.97 per share, beating the Zacks Consensus Estimate of $1.91 per share. This compares to earnings of $1.75 per share a year ago.
While the top- and bottom-line numbers for Ametek (AME) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
, /PRNewswire/ -- AMETEK, Inc. (NYSE: AME) today announced that it has entered into a definitive agreement to acquire a portfolio of instrumentation businesses from Indicor, LLC ("Indicor Instrumentation") in an all‑cash transaction valued at approximately $5.0 billion.
Indicor Instrumentation is a group of leading businesses that design and manufacture mission critical solutions for demanding industrial and scientific applications. Its products serve customers across attractive end markets that align closely with AMETEK's existing portfolio and generate a substantial base of recurring revenue from consumables, services, and aftermarket support.
"Indicor is an exceptional fit for AMETEK," said David A. Zapico, AMETEK Chairman and Chief Executive Officer. "In a single transaction, we are adding a high-quality group of businesses with differentiated technologies, complementary market positions, and attractive growth prospects. We see meaningful potential to create value through integration into AMETEK's operating model."
Indicor Instrumentation generates approximately $1.1 billion in annual sales and has profitability levels consistent with AMETEK. Following closing of the transaction, the businesses will be integrated into AMETEK's Electronic Instruments Group (EIG) and Electromechanical Group (EMG) based on product offerings and market alignment.
AMETEK plans to fund the acquisition through borrowings under its existing credit facility and new debt issuance. The transaction is subject to customary closing conditions, including applicable regulatory approvals, and is expected to close in the second half of 2026.
AMETEK will host a conference call to discuss the acquisition at 8:00 a.m. Eastern Time on May 6, 2026. The live audio webcast will be available and later archived in the Investors section of www.ametek.com.
Corporate Profile
AMETEK (NYSE: AME) is a leading global provider of industrial technology solutions serving a diverse set of attractive niche markets with annual sales of approximately $7.5 billion. The AMETEK Growth Model integrates the Four Growth Strategies - Operational Excellence, Technology Innovation, Global and Market Expansion, and Strategic Acquisitions - with a disciplined focus on cash generation and capital deployment. AMETEK's objective is double-digit percentage growth in earnings per share over the business cycle and a superior return on total capital. Founded in 1930, AMETEK has been listed on the NYSE for over 95 years and is a component of the S&P 500. For more information, visit www.ametek.com.
Contact:
Kevin Coleman
Vice President, Investor Relations and Treasurer
[email protected]
Phone: 610-889-5247
3D Printing is reshaping industries with faster production and lower costs, drawing investor interest. Stocks like NVDA, AME, CRS and ATI offer strong growth potential.
Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- The Board of Directors of AMETEK, Inc. (NYSE: AME) declared a regular quarterly dividend of $0.34 per share for the second quarter ending June 30, 2026.
This second quarter dividend is payable June 30, 2026 to shareholders of record as of June 15, 2026.
Corporate Profile:
AMETEK (NYSE: AME) is a leading global provider of industrial technology solutions serving a diverse set of attractive niche markets with annual sales of approximately $7.5 billion. The AMETEK Growth Model integrates the Four Growth Strategies - Operational Excellence, Technology Innovation, Global and Market Expansion, and Strategic Acquisitions - with a disciplined focus on cash generation and capital deployment. AMETEK's objective is double-digit percentage growth in earnings per share over the business cycle and a superior return on total capital. Founded in 1930, AMETEK has been listed on the NYSE for over 95 years and is a component of the S&P 500. For more information, visit www.ametek.com.
Contact:
Kevin Coleman
Vice President, Investor Relations and Treasurer
[email protected]
Phone: 610.889.5247
Research Tools All Access Research Tools Live News Feed Momentum Alerts Idea Engine Export Data (CSV) See All Research Tools My MarketBeat My Portfolio My Newsletter My Account Calculators Dividend Calculator Dividend Yield Calculator Market Cap Calculator Options Profit Calculator Stock Average Calculator Stock Split Calculator Stock Profit Calculator Stock Screeners Stock Screener ETF Screener Stock Ratings Screener Dividend Screener Earnings Screener Updated Insider Trades Screener Updated Trending Stocks Trending MarketBeat Stocks Trending Media Mentions High Media Sentiment Stocks Premium Reports The Rise of the Robots NewBeginner's Guide to 5G Stocks New10 Stocks Set to Soar in 2026 NewEssential Insights: Almost Everything You Need to Know About the EV Market New7 AI Stocks to Invest In 10 Best High-Yield Dividend Stocks Hottest IPOs 7 Best Space Stocks Premium Articles Financial Calendars Calendars and Market Data Market Data All Market Data and Financial Calendars Analyst Ratings Recent Analyst Ratings Stock Ratings Screener Top-Rated Stocks Lowest-Rated Stocks Top-Rated Analysts Top-Rated Brokerages Most-Upgraded Stocks Free Ratings Newsletter Congressional Data Recent Trades Most Bought Stocks Members of Congress Corporate Events Corporate Buybacks Initial Public Offerings (IPOs) IPO Lockup Expirations SEC Filings Stock Splits Dividends Today's Announcements Ex-Dividend Calendar Dividend Increases Dividend Achievers Best Dividend Stocks High-Yield Dividend Stocks Top-Rated Dividend Stocks Dividend Screener Free Dividend Newsletter Earnings Today's Announcements Tomorrow's Announcements Next Week's Announcements Upcoming Earnings Calls Earnings Call Transcripts Earnings Screener Updated Upcoming FDA Calendar Recent FDA Calendar Insider Trades Today's Insider Trades Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Updated Insider Trades Newsletter Stock Market Holidays Cryptocurrencies All Cryptocurrencies Cryptocurrency Headlines Cryptocurrency Newsletter Gainers & Decliners Percentage Gainers Percentage Decliners Pre-Market Movers After Hours Movers Breakout Stocks High & Low P/E High P/E Stocks Low P/E Stocks Highs & Lows 52-Week Highs 52-Week Lows Most Active Most Active Stocks Most Volatile Stocks Unusual Trading Volume Trading Halts Options Unusual Call Volume Unusual Put Volume Sector Performance Short Interest Largest Short Positions Short Interest Increases Short Interest Decreases Stock Lists All Stock Lists Stocks by Interest 5G Stocks Blue Chip Stocks Biotech Stocks FAANG Stocks Gold Stocks Large Cap Stocks Marijuana Stocks Oil Stocks REITs Russell 2000 Stocks Small Cap Stocks Warren Buffett Stocks Low Priced Stocks Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $5 Penny Stocks Most Active Penny Stocks Most Popular Penny Stocks Top Penny Stocks Today Stocks by Exchange NYSE Stocks NASDAQ Stocks OTCMKTS Stocks TSX Stocks LSE Stocks Stocks by Sector Automotive Stocks Aerospace Stocks Basic Materials Stocks Business Services Stocks Consumer Discretionary Stocks Consumer Staples Stocks Construction Stocks Energy Stocks Finance Stocks Industrial Stocks Manufacturing Stocks Medical Stocks Real Estate Stocks Retail Stocks Technology Stocks Transportation Stocks Utilities Stocks Technical Indicators Death Cross Stocks Golden Cross Stocks RSI Overbought Stocks RSI Oversold Stocks Stock Comparisons Premium Stock Lists Top MarketRank™ Stocks Top-Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Headlines News & Analysis AI Analyst Ratings Biotech Dividends Earnings Electric Vehicles ETFs Insider Trades IPOs Macro Markets Mergers & Acquisitions Rare Earth Minerals Semiconductors Short Interest Space MarketBeat TV Stock Ideas Get trade ideas with thorough analysis of stocks that are poised to move.
Financial Terms Learn investing concepts from our glossary of over 200 financial terms.
Research Surveys Gain valuable insights into financial trends and economic impacts from consumer research studies.
Real-Time News Feed View real-time investing headlines and stock market news for your watchlist or the broader market.
MarketBeat Instant News Alerts Trending News All MarketBeat Instant News Alerts Sort By
Time Frame
Alert Type
Keywords
Page 1 of 323
Get 30 Days of MarketBeat All Access for Free
Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools.
Start Your 30-Day Trial
Sign in to your free account to enjoy these benefits
In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer.
Research Tools All Access Research Tools Live News Feed Momentum Alerts Idea Engine Export Data (CSV) See All Research Tools My MarketBeat My Portfolio My Newsletter My Account Calculators Dividend Calculator Dividend Yield Calculator Market Cap Calculator Options Profit Calculator Stock Average Calculator Stock Split Calculator Stock Profit Calculator Stock Screeners Stock Screener ETF Screener Stock Ratings Screener Dividend Screener Earnings Screener Updated Insider Trades Screener Updated Trending Stocks Trending MarketBeat Stocks Trending Media Mentions High Media Sentiment Stocks Premium Reports The Rise of the Robots NewBeginner's Guide to 5G Stocks New10 Stocks Set to Soar in 2026 NewEssential Insights: Almost Everything You Need to Know About the EV Market New7 AI Stocks to Invest In 10 Best High-Yield Dividend Stocks Hottest IPOs 7 Best Space Stocks Premium Articles Financial Calendars Calendars and Market Data Market Data All Market Data and Financial Calendars Analyst Ratings Recent Analyst Ratings Stock Ratings Screener Top-Rated Stocks Lowest-Rated Stocks Top-Rated Analysts Top-Rated Brokerages Most-Upgraded Stocks Free Ratings Newsletter Congressional Data Recent Trades Most Bought Stocks Members of Congress Corporate Events Corporate Buybacks Initial Public Offerings (IPOs) IPO Lockup Expirations SEC Filings Stock Splits Dividends Today's Announcements Ex-Dividend Calendar Dividend Increases Dividend Achievers Best Dividend Stocks High-Yield Dividend Stocks Top-Rated Dividend Stocks Dividend Screener Free Dividend Newsletter Earnings Today's Announcements Tomorrow's Announcements Next Week's Announcements Upcoming Earnings Calls Earnings Call Transcripts Earnings Screener Updated Upcoming FDA Calendar Recent FDA Calendar Insider Trades Today's Insider Trades Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Updated Insider Trades Newsletter Stock Market Holidays Cryptocurrencies All Cryptocurrencies Cryptocurrency Headlines Cryptocurrency Newsletter Gainers & Decliners Percentage Gainers Percentage Decliners Pre-Market Movers After Hours Movers Breakout Stocks High & Low P/E High P/E Stocks Low P/E Stocks Highs & Lows 52-Week Highs 52-Week Lows Most Active Most Active Stocks Most Volatile Stocks Unusual Trading Volume Trading Halts Options Unusual Call Volume Unusual Put Volume Sector Performance Short Interest Largest Short Positions Short Interest Increases Short Interest Decreases Stock Lists All Stock Lists Stocks by Interest 5G Stocks Blue Chip Stocks Biotech Stocks FAANG Stocks Gold Stocks Large Cap Stocks Marijuana Stocks Oil Stocks REITs Russell 2000 Stocks Small Cap Stocks Warren Buffett Stocks Low Priced Stocks Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $5 Penny Stocks Most Active Penny Stocks Most Popular Penny Stocks Top Penny Stocks Today Stocks by Exchange NYSE Stocks NASDAQ Stocks OTCMKTS Stocks TSX Stocks LSE Stocks Stocks by Sector Automotive Stocks Aerospace Stocks Basic Materials Stocks Business Services Stocks Consumer Discretionary Stocks Consumer Staples Stocks Construction Stocks Energy Stocks Finance Stocks Industrial Stocks Manufacturing Stocks Medical Stocks Real Estate Stocks Retail Stocks Technology Stocks Transportation Stocks Utilities Stocks Technical Indicators Death Cross Stocks Golden Cross Stocks RSI Overbought Stocks RSI Oversold Stocks Stock Comparisons Premium Stock Lists Top MarketRank™ Stocks Top-Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Headlines News & Analysis AI Analyst Ratings Biotech Dividends Earnings Electric Vehicles ETFs Insider Trades IPOs Macro Markets Mergers & Acquisitions Rare Earth Minerals Semiconductors Short Interest Space MarketBeat TV Stock Ideas Get trade ideas with thorough analysis of stocks that are poised to move.
Financial Terms Learn investing concepts from our glossary of over 200 financial terms.
Research Surveys Gain valuable insights into financial trends and economic impacts from consumer research studies.
Real-Time News Feed View real-time investing headlines and stock market news for your watchlist or the broader market.
MarketBeat Instant News Alerts Trending News All MarketBeat Instant News Alerts Sort By
Time Frame
Alert Type
Keywords
Page 1 of 323
Get 30 Days of MarketBeat All Access for Free
Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools.
Start Your 30-Day Trial
Sign in to your free account to enjoy these benefits
In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer.
Ametek (AME) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Ametek, Inc. is positioned for durable growth, leveraging megatrends in aerospace & defense, semiconductors, and data centers. Recent acquisitions—First Aviation and Indicor ($5B)—significantly expand AME's aerospace, defense, and instrumentation capabilities, with value accretion expected from late 2026. I reiterate my buy rating on AME stock with a $272/share price target at 20.23x eFY28 EV/aEBITDA, citing robust market dynamics and strategic expansion.
, /PRNewswire/ -- AMETEK, Inc. (NYSE: AME) today announced that it has completed its acquisition of First Aviation Services, a leading provider of highly engineered defense and aviation maintenance, repair and overhaul (MRO) services and a manufacturer of related proprietary components.
"We are excited to welcome the First Aviation team to AMETEK," said David A. Zapico, AMETEK Chairman and Chief Executive Officer. "First Aviation is an excellent strategic fit with our existing MRO business, creating attractive opportunities for market expansion and added scale in support of mission-critical aerospace and defense applications. Their proprietary products and services nicely complement AMETEK's capabilities and strengthen our position across attractive platforms."
First Aviation's MRO capabilities include advanced electronics, rotor blades and assemblies, propellers, landing gear, and flight controls. In addition, the company specializes in the design, engineering, and manufacturing of critical parts across a wide range of defense and aviation platforms.
First Aviation Services generates approximately $80 million in annual revenue and operates six centers of excellence throughout the U.S. They join AMETEK as part of its Electromechanical Group (EMG).
Corporate Profile
AMETEK (NYSE: AME) is a leading global provider of industrial technology solutions serving a diverse set of attractive niche markets with annual sales of approximately $7.5 billion. The AMETEK Growth Model integrates the Four Growth Strategies - Operational Excellence, Technology Innovation, Global and Market Expansion, and Strategic Acquisitions - with a disciplined focus on cash generation and capital deployment. AMETEK's objective is double-digit percentage growth in earnings per share over the business cycle and a superior return on total capital. Founded in 1930, AMETEK has been listed on the NYSE for over 95 years and is a component of the S&P 500. For more information, visit www.ametek.com.
Contact:
Kevin Coleman
Vice President, Investor Relations and Treasurer
[email protected]
Phone: 610-889-5247
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present 38 abstracts, as well as one oral presentation in partnership with Pfizer, showcasing advances in methylation-based tumor classification and liquid biopsy technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois taking place May 29 – June 2, 2026.
Key data that will be presented include:
Abstract #3077 validating the use of Guardant360 Liquid CDx as a companion diagnostic for therapy selection and comprehensive pan-cancer tumor profiling in routine oncology practice. Findings led to recent FDA approval of the IVD assay, marking the world’s largest FDA-approved liquid biopsy panel, demonstrating how incorporating both genomic and epigenomic signals for variant detection produces strong analytical sensitivity, accuracy, and specificity across clinically relevant alterations. Abstract #3070 revealing the potential of Guardant360 Liquid in expanding access to targeted ALK inhibitor therapy and getting the right treatment to lung patients faster. Demonstrating advanced detection missed by standard genomic methods, the analysis demonstrated improved detection of actionable ALK fusions in non-small cell lung cancer (NSCLC) while maintaining high specificity by identifying additional ALK fusion-positive cases. Abstract #TPS10632 evaluating longitudinal performance of the Shield blood test for primary colorectal cancer screening in its intended use population, building off the strong performance in the prospective, observational ECLIPSE study that led to FDA approval. “Our presence at this year’s ASCO reflects the power of liquid biopsy tests to provide oncologists with actionable insights to more effectively treat patients in a faster amount of time,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO. “Guardant’s Smart Platform, an AI-enabled multiomic technology platform behind our next generation of cancer tests, is fueling the entire portfolio and supporting new clinical applications across the cancer care continuum.”
Key Guardant Health and collaborator presentations at ASCO 2026
Presentation
Title
Time / Location
8502
Lorlatinib vs crizotinib as first-line treatment for advanced ALK+ non-small cell lung cancer: 7-year update from the phase 3 CROWN study
May 29, 2026 / 1:00 - 4:00 PM CDT
3525 / 279
A deep learning approach to quantify tumor microenvironment features associated with postoperative ctDNA status and outcomes in a phase III FOLFOX-based adjuvant colon cancer trial (N0147; Alliance)
May 30, 2026 / 9:00 AM - 12:00 PM CDT
3546 / 313
A multicenter single-arm phase II trial evaluating the safety and efficacy of panitumumab and irinotecan in NeoRAS wild-type metastatic colorectal cancer patients (C-PROWESS)
May 30, 2026 / 9:00 AM - 12:00 PM CDT
3572 / 339
Circulating tumor DNA (ctDNA) tumor fraction (TF) dynamics to refine progression-free survival and radiographic response during anti-EGFR rechallenge in metastatic colorectal cancer
May 30, 2026 / 9:00 AM - 12:00 PM CDT
3659 / 426
Evaluation of circulating tumor DNA (ctDNA) burden, detected mutations and clinical outcomes in metastatic colorectal cancer (mCRC) using real-world data (RWD)
May 30, 2026 / 9:00 AM - 12:00 PM CDT
4050 / 33
Molecular circulating tumor DNA (ctDNA) profiling from patients (pts) treated with zanidatamab + chemotherapy (CT) in first-line (1L) HER2-positive (HER2+) advanced or metastatic gastroesophageal adenocarcinoma (mGEA)
May 30, 2026 / 9:00 AM - 12:00 PM CDT
4159 / 142
First-line GemCis ± immunotherapy vs FGFR inhibition in ctDNA-detected FGFR2 fusion-positive advanced cholangiocarcinoma: a real-world analysis
May 30, 2026 / 9:00 AM - 12:00 PM CDT
4161 / 144
Real-world analysis of epigenomic molecular tumor-type prediction for biliary tract cancer in CUP
May 30, 2026 / 9:00 AM - 12:00 PM CDT
4238 / 221
Real-world outcomes in gastrointestinal cancer patients with targetable genomic alterations identified on serial liquid biopsy
May 30, 2026 / 9:00 AM - 12:00 PM CDT
3051 / 188
Tumor-of-origin prediction using methylation signals from plasma cell-free DNA (cfDNA): Real-world experience in Asia and the Middle East (AME)
May 30, 2026 / 1:30 - 4:30 PM CDT
3052 / 189
Tissue-free minimal residual disease evaluation and clinical utility in early breast cancer: a real-world study
May 30, 2026 / 1:30 - 4:30 PM CDT
3070 / 207
Cell-free DNA methylation profile-based fusion epigenotyping to enhance ALK fusion detection in NSCLC patients
May 30, 2026 / 1:30 - 4:30 PM CDT
3077 / 214
Analytical validation of a plasma-based cfDNA NGS assay (Guardant360 Liquid CDx) for comprehensive solid tumor profiling
May 30, 2026 / 1:30 - 4:30 PM CDT
3105 / 242
Phase II basket trial of brigatinib for ALK fusion–positive solid tumors: ALLBREAK trial (WJOG15221M)
May 30, 2026 / 1:30 - 4:30 PM CDT
1031 / 145
Concordance between liquid and tissue biopsy in participants with newly diagnosed recurrent breast cancer
June 1, 2026 / 1:30 - 4:30 PM CDT
1095 / 209
Liquid-based methylation profiling of molecular breast cancer subtypes (MBS) in hormone receptor positive (HR+) metastatic breast cancer (MBC) treated with CDK4/6 inhibitor (CDK4/6i)
June 1, 2026 / 1:30 - 4:30 PM CDT
The full abstracts for Guardant Health and a list of all abstracts being presented at ASCO 2026 can be found on the ASCO website.
About Guardant360® Liquid CDx
The largest FDA-approved liquid biopsy, Guardant360 Liquid CDx is the only FDA-approved liquid biopsy test integrating genomic and epigenomic data for comprehensive insights. Guardant360 Liquid CDx is approved as a companion diagnostic for multiple therapies in non-small cell lung cancer and colorectal cancer. It is also the only FDA-approved companion diagnostic for targeted therapy in advanced breast cancer patients with ESR1 mutations. The test is broadly covered by Medicare and commercial insurers, representing over 300 million lives.
About Guardant360 Liquid
Guardant360 Liquid is a blood-based test that analyzes tumor DNA fragments circulating in the blood (cfDNA) to identify genetic mutations in advanced solid tumors, helping oncologists find targeted therapies. It offers an alternative to tissue biopsies, providing comprehensive genomic profiling (CGP) to guide personalized treatment for a wide range of solid cancers including lung, breast, colorectal, and prostate cancer. Guardant360 Liquid is guideline-complete across all advanced solid tumors, and has been clinically validated in more than 1,500 publications and research abstracts.
About Guardant Reveal
Guardant Reveal is a tissue-free liquid biopsy test that detects minimal residual disease (MRD) and monitors recurrence in early-stage colorectal, breast, and lung cancers, helping oncologists guide treatment decisions. In addition to MRD detection, Reveal can be used for late-stage therapy response monitoring for patients with solid tumors. Guardant Reveal therapy response monitoring can be initiated at any time during a patient’s treatment journey, offering clinicians flexibility and actionable insights.
The first clinical-validation study of pan-cancer chemotherapy monitoring published in The Journal of Liquid Biopsyshowed that Guardant Reveal predicts long-term patient benefit up to 18 months earlier than standard clinical measures.
About Shield
Shield is a methylation partitioning cell-free DNA (mp-cfDNA) non-invasive, blood-based screening test that detects alterations associated with colorectal cancer in the blood. It is intended as a screening test for individuals at average risk for the disease, age 45 or older, and is not intended for individuals at high risk for colorectal cancer. The Shield test can be considered in a manner similar to guideline-recommended non-invasive CRC screening options and can be completed during any healthcare visit. A positive Shield result raises concern for the presence of colorectal cancer or advanced adenoma and the patient should be referred for colonoscopy evaluation.
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
Guardant Health Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2025 and in its other reports filed with or furnished to the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260528810245/en/
Nes Ziona, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- QTREX Quantum Ltd. (Nasdaq: QTEX) ("QTREX" or the "Company") a company focused on advancing Additively Manufactured Electronics (“AME”) for quantum computing infrastructure, today announced that it received a purchase order from a Fortune 500 multinational company for an AME system and related materials. The customer is headquartered in the United States, and the AME system will be delivered to one of the customer’s sites outside the United States.
QTREX’s AME system is designed to provide the customer a unique capability that cannot be achieved through conventional technologies: the ability to create intricate structures with advanced materials and customized architectures in a single workflow. This capability is designed to enable higher complexity and a path toward applications where traditional manufacturing reaches its physical limits.
The order expands QTREX’s commercial AME footprint with a global enterprise customer and reinforces the Company’s position as an advanced AME platform for demanding technology environments and is expected to contribute to the Company’s upcoming financial results, further strengthening QTREX’s growing AME commercial activity.
"Conventional manufacturing is reaching its limits in advanced electronics," said Dagi Ben-Noon, CEO of QTREX. "Our AME platform provides capabilities that conventional technologies simply cannot replicate, and that advantage is most visible in quantum connectivity, where the density, materials integration and design freedom required for scale cannot be achieved any other way. Together with our recently announced orders, we are establishing a commercial revenue base that already exceeds the most recently reported annual revenues of certain publicly traded quantum computing companies.”
The Company is actively engaging with additional prospective tier-1 customers and expects to provide further updates as its AME commercial pipeline and quantum infrastructure programs continue to advance.
About QTREX Quantum
QTREX Quantum Ltd. (Nasdaq: QTEX) is a technology company focused on advanced connectivity and electronics manufacturing solutions for next-generation hardware markets. Following its acquisition of the AME platform, the Company is developing high-density, thermally optimized quantum connectivity solutions for dilution cryostats and advancing AME applications for defense, aerospace, missile, space, and other mission-critical environments. The Company also continues to advance its medical technology portfolio, including respiratory support and blood monitoring platforms, while actively working to monetize certain parts of the medical business. For more information, please visit: www.q-trex.com
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses the benefits of its AME products, that the order expands its commercial AME footprint and reinforces its position as an advanced AME platform for demanding technology environments and further strengthening its growing AME commercial activity and that it is expected to contribute to the Company’s upcoming financial results, that its AME platform provides capabilities it believes conventional technologies simply cannot replicate, that advantage in its AME platform is most visible in quantum connectivity, that it is establishing a revenue base, that it is engaging with additional prospective tier-1 customers and that it expects to provide further updates as its AME commercial pipeline and quantum infrastructure programs continue to advance. These forward-looking statements and their implications are based solely on the current expectations of the Company’s management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (the “SEC”), which is available on the SEC’s website at www.sec.gov.
Company Contact
QTREX Quantum
Email: [email protected]
Phone: +972-9-9664485
Investor Relations Contact:
Arx Investor Relations
North American Equities Desk [email protected]
Nes Ziona, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- QTREX Quantum Ltd. (Nasdaq: QTEX) ("QTREX" or the "Company") a company focused on advancing Additively Manufactured Electronics (“AME”) for quantum computing infrastructure, today announced that Mr. Tal Parnas, Chairman of the Company’s Board of Directors, and Mr. Yoav Rozanovich, the Company’s Chief Business Officer, will be in Boston, Massachusetts during Quantum.Tech World 2026 on June 25–26, 2026, to present functional AME-based monolithic connectivity components engineered for quantum computing systems.
QTREX will conduct private, invitation-only meetings with industry leaders, research institutions and strategic partners in a dedicated meeting suite adjacent to the conference venue. Meetings will be scheduled in advance through Mr. Yoav Rozanovich.
The Company will present fabricated, functional monolithic connectivity components produced using its proprietary AME platform components, specifically engineered to address cryogenic interconnect challenges in superconducting quantum systems. These components demonstrate high-density signal routing, advanced dielectric materials integration and complex 3D architectures designed for scalable quantum hardware operating under extreme cryogenic conditions. QTREX is among a small number of companies worldwide with demonstrated capability to additively manufacture such components at this level of technical specification.
Quantum.Tech World 2026 is among the foremost global forums for the commercialization of quantum technologies, bringing together leading quantum hardware developers, systems integrators, enterprise adopters, government stakeholders and research institutions. QTREX’s participation reflects the Company’s position at the hardware frontier of quantum computing infrastructure, where the interconnect challenges that constrain scalability are now being addressed through physical, manufacturable components.
Industry participants and potential partners interested in scheduling a private meeting with QTREX during Quantum.Tech World 2026 may contact:
Mr. Yoav Rozanovich
Chief Business Officer, QTREX Quantum Ltd.
Email: [email protected]
About QTREX Quantum
QTREX Quantum Ltd. (Nasdaq: QTEX) is a technology company focused on advanced connectivity and electronics manufacturing solutions for next-generation hardware markets. Following its acquisition of the AME platform, the Company is developing high-density, thermally optimized quantum connectivity solutions for dilution cryostats and advancing AME applications for defense, aerospace, missile, space, and other mission-critical environments. The Company also continues to advance its medical technology portfolio, including respiratory support and blood monitoring platforms, while actively working to monetize certain parts of the medical business. For more information, please visit: www.q-trex.com
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses the benefits and advantages of its products and that QTREX’s participation at Quantum.Tech World 2026 reflects the Company’s position at the hardware frontier of quantum computing infrastructure. These forward-looking statements and their implications are based solely on the current expectations of the Company’s management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (the “SEC”), which is available on the SEC’s website at www.sec.gov.
Company Contact
QTREX Quantum
Email: [email protected]
Phone: +972-9-9664485
Investor Relations Contact:
Arx Investor Relations
North American Equities Desk [email protected]
